Advanced Enzyme Technologies closes Rs 69.696 crore buyback
Key highlights
- Advanced Enzyme Technologies repurchased 24.10906 lakh equity shares for Rs 69.696 crore by 30 October 2026.
- The buyback utilised 99.99% of the approved Rs 69.70 crore limit, excluding transaction costs.
- Paid-up equity share capital fell to Rs 2.2053 crore at 30 September 2026 from Rs 2.2385 crore at 31 March 2026.
- Consolidated net profit rose to Rs 89.742 crore in the six months ended 30 September 2026 from Rs 85.173 crore a year earlier.
powered by IRIS

Advanced Enzyme Technologies Limited has closed its open-market buyback after repurchasing 24.10906 lakh equity shares for Rs 69.696 crore, excluding transaction costs. Advanced Enzyme Technologies used 99.99% of its Rs 69.70 crore approved buyback size, and its Buyback Committee approved closure on 30 October 2026. Shares purchased during October remain to be extinguished.
Know Advanced Enzyme Technologies inside out
Results, valuation, peers and who's buying, in one view.
How much did Advanced Enzyme Technologies spend on the buyback?
Advanced Enzyme Technologies utilised Rs 69.696 crore, excluding transaction costs, to buy 24.10906 lakh equity shares by 30 October 2026. That represented 99.99% of the Rs 69.70 crore maximum buyback size approved by the board, and the Buyback Committee approved closure of the programme on 30 October 2026.
The board approved the buyback on 8 August 2026, and purchases commenced on 14 August 2026. Advanced Enzyme Technologies used the open-market route through the stock-exchange mechanism to buy fully paid equity shares with a face value of Rs 2 each from eligible shareholders other than promoters, the promoter group and persons in control.
The maximum purchase price was Rs 500 per share. At that price, the company had indicated a maximum of 13.94 lakh shares, or about 1.24% of paid-up capital, but it ultimately bought 24.10906 lakh shares while remaining within the approved cash limit because market purchases occurred below the maximum price.
What happened to shares bought before 30 September 2026?
Advanced Enzyme Technologies had bought 17.13324 lakh shares by 30 September 2026 for total cash consideration of Rs 52.077 crore, including Rs 87.8 lakh of buyback-related expenses and transaction costs. The final utilisation of Rs 69.696 crore excluded transaction costs and included purchases made during October.
Of the shares purchased by 30 September, 8.25028 lakh were extinguished on 7 September 2026, according to depository records. The remaining 8.88296 lakh shares were extinguished on 7 October 2026, after the half-year reporting date but before the Buyback Committee closed the programme on 30 October.
Advanced Enzyme Technologies treated the 7 October extinguishment as an adjusting event under Indian Accounting Standard 10, Events after the Reporting Period. The company said those shares had already been bought by 30 September and that only the formal extinguishment process was pending, so it accounted for the full September buyback in the quarter and six-month results.
The accounting treatment means the reported capital position at 30 September included the shares acquired before that date, despite part of the procedural cancellation occurring in October. Paid-up equity share capital stood at Rs 2.2053 crore on 30 September 2026, compared with Rs 2.2385 crore at 31 March 2026, a reduction of Rs 3.32 lakh.
How did Advanced Enzyme Technologies account for the repurchase?
Advanced Enzyme Technologies used Rs 51.734 crore from the securities premium account for the buyback, representing consideration above the face value of shares and transaction costs. It also created a capital redemption reserve of Rs 34.3 lakh, equal to the nominal value of shares bought back, through an appropriation from surplus in the statement of profit and loss.
The company said these steps followed Section 69 of the Companies Act, 2013. The Rs 2 face value of each share was substantially below the Rs 500 maximum purchase price, which is why the company drew on securities premium for consideration above nominal value and related costs.
The consolidated cash-flow statement recorded Rs 52.077 crore for the buyback, including expenses, during the six months ended 30 September 2026. This was part of Rs 72.308 crore of net cash used in financing activities during the period, which also included Rs 15.517 crore in dividends paid.
The difference between the half-year cash-flow amount and the final utilisation reflects both timing and presentation. The Rs 52.077 crore figure covered 17.13324 lakh shares by 30 September and included costs, whereas Rs 69.696 crore covered 24.10906 lakh shares purchased by 30 October and excluded transaction costs.
Got a follow-up? Ask IRIS
What do the approved limits show about the buyback?
Advanced Enzyme Technologies set the Rs 69.70 crore ceiling at 9.99% of standalone paid-up equity share capital and free reserves, and 5.09% of the corresponding consolidated amount, based on audited financial statements at 31 March 2026. The company said each measure was within the 10% threshold under the applicable buyback regulations.
The buyback used an open-market mechanism rather than a tender offer. Under that route, the number of shares acquired depends on market prices, allowing Advanced Enzyme Technologies to purchase more than the 13.94 lakh-share illustration while keeping cash utilisation within the board-approved Rs 69.70 crore cap.
Total consolidated equity was Rs 171.9895 crore at 30 September 2026, compared with Rs 168.3122 crore at 31 March 2026. Equity attributable to owners was Rs 166.4791 crore at 30 September, comprising Rs 2.2053 crore of equity share capital and Rs 164.2738 crore of other equity.
The decline in share capital was one component of the equity movement, while the half-year accounts also reported consolidated net profit of Rs 89.742 crore. That compared with Rs 85.173 crore in the six months ended 30 September 2025, an increase of Rs 4.569 crore.
When will Advanced Enzyme Technologies extinguish the October shares?
Advanced Enzyme Technologies said the shares purchased during October 2026 will be extinguished in accordance with applicable provisions of the Companies Act, 2013. The announcement did not disclose a date for this final extinguishment, unlike the 7 September and 7 October dates provided for shares bought by 30 September.
The pending cancellation relates to October purchases, rather than the 17.13324 lakh shares already reflected in the 30 September results. At the reporting date the buyback remained open, and by 30 October Advanced Enzyme Technologies had reached 24.10906 lakh shares and utilised 99.99% of the approved amount.
The board approved the unaudited consolidated results on 31 October 2026, one day after the Buyback Committee approved closure. The statutory auditors reviewed the consolidated results and expressed an unmodified conclusion, while the company reported that the buyback had been fully accounted for through 30 September for shares acquired by that date.
Conclusion
Advanced Enzyme Technologies has substantially completed its approved repurchase, using Rs 69.696 crore, excluding transaction costs, or 99.99% of the Rs 69.70 crore limit. The company bought 24.10906 lakh shares, exceeding its 13.94 lakh-share maximum-price illustration because purchases were below Rs 500 per share, while paid-up capital declined by Rs 3.32 lakh between 31 March and 30 September 2026.
The next disclosed step is the extinguishment of equity shares purchased during October 2026. Advanced Enzyme Technologies has not provided a cancellation date, so the formal extinguishment filing is the remaining event to watch following the Buyback Committee’s 30 October 2026 closure decision.


